Utama › Leukemia Limfositik Kronik › Rhode Island
Kajian klinikal Leukemia Limfositik Kronik di Rhode Island
6 kajian untuk Leukemia Limfositik Kronik sedang mencari peserta di lokasi di Rhode Island.
Bandar di Rhode Island
Teks kajian rasmi (Bahasa Inggeris)
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
- Rhode Island Hospital, Providence
Mengambil pesertaFasa 3
Umur 65 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT07321652Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Kent Hospital, Warwick
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 40 hingga 75 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT05334069A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
- Research Site, Providence
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 8 Sep 2026 · NCT06564038Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Lifespan Cancer Institute at Rhode Island Hospital, Providence
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 8 Sep 2026 · NCT03666000A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
- Lifespan Cancer Institute - Providence /ID# 266550, Providence
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 9 Apr 2026 · NCT06428019Study of SGR-1505 in Mature B-Cell Neoplasms
- Rhode Island Hospital, Providence
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 13 Feb 2026 · NCT05544019Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.